Showing results (441-450 of 463) with videos related to

Sort By:
Pageof 47
Clinical Transplantation|October 14, 2025
Clinical Utility of Combined Donor-Derived Cell-Free DNA and Peripheral Gene-Expression-Profiling in Heart Transplant RecipientsCathrine M Moeller, Andrea Fernandez Valledor, Daniel Oren, et al.
Blood Advances|November 24, 2020
Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosisAaron T Gerds, Michael R Savona, Bart L Scott, et al.
JCO Precision Oncology|May 26, 2021
Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid LeukemiaErica K Barnell, Kenneth F Newcomer, Zachary L Skidmore, et al.
Nature Medicine|March 11, 2025
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trialRaajit K Rampal, Sebastian Grosicki, Dominik Chraniuk, et al.
Leukemia|October 4, 2024
Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment responseMeagan A Jacoby, Eric D Duncavage, Ajay Khanna, et al.
Lancet Regional Health. Americas|June 17, 2026
Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET)Brandi N Reeves, Firas El Chaer, Lynda Foltz, et al.
The Lancet. Haematology|November 5, 2025
Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 studyRuben Mesa, Harinder Gill, Lei Zhang, et al.
Retina (Philadelphia, Pa.)|October 20, 2020
CLINICAL OUTCOMES AND TREATMENT COURSE OF EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION FOLLOWING THE DEVELOPMENT OF ENDOPHTHALMITISNicole Koulisis, Stavros N Moysidis, Viren K Govindaraju, et al.
Nature Communications|January 27, 2026
Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trialTim Kong, Alex Mabry, Maureen Highkin, et al.
Nature Communications|May 8, 2021
Co-evolution of tumor and immune cells during progression of multiple myelomaRuiyang Liu, Qingsong Gao, Steven M Foltz, et al.
Pageof 47